PRA023 IV ( DrugBank: - )

3 diseases

51. 全身性強皮症

臨床試験数 : 523 / 薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05270668 (ClinicalTrials.gov)	February 22, 2022	27/2/2022	Phase 2 Safety and Efficacy Study of PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD)	A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD)	Diffuse Cutaneous Systemic Sclerosis;Interstitial Lung Disease	Drug: PRA023 IV;Device: Companion diagnostic ( CDx);Drug: Placebo	Prometheus Biosciences, Inc.	PPD	Recruiting	18 Years	N/A	All	100	Phase 2	United States

臨床試験数 : 2,400 / 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05013905 (ClinicalTrials.gov)	July 28, 2021	13/8/2021	A Phase 2a Safety and Efficacy Open-Label Study of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease	A Phase 2a, Multi-Center, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease	Crohn Disease	Drug: PRA023 IV;Device: Companion diagnostic (CDx)	Prometheus Biosciences, Inc.	NULL	Recruiting	18 Years	N/A	All	50	Phase 2	United States

臨床試験数 : 2,527 / 薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04996797 (ClinicalTrials.gov)	July 14, 2021	2/8/2021	A Phase 2 Safety and Efficacy Study of PRA023 in Subjects With Moderately to Severely Active Ulcerative Colitis	A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Induction Therapy With PRA023 in Subjects With Moderately to Severely Active Ulcerative Colitis	Ulcerative Colitis	Drug: PRA023 IV;Device: Companion Diagnostic (CDx) Testing;Other: Placebo	Prometheus Biosciences, Inc.	NULL	Recruiting	18 Years	N/A	All	170	Phase 2	United States